Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Pittsburg, Pennsylvania 15213


Purpose:

This study evaluates the effect of using remifentanil during cardiopulmonary bypass surgery to supress the hyperglycemic response in perioperative period. Half of the participants will receive continuous intravenous remifentanil during surgery, while the other half will receive intermittent intravenous fentanyl during surgery. Intermittent intravenous fentanyl administration is this institution's standard of care.


Study summary:

Stress-induced hyperglycemia is a well-known phenomena that occurs during cardiopulmonary bypass surgery. Hyperglycemia increases the incidence of major adverse events and mortality in patients undergoing cardiac surgery. Remifentanil, an ultra-short acting opioid analgesic, has been shown to reduce the stress response to cardiopulmonary bypass when compared to intermittent fentanyl and inhalation anesthesia. This in turn, will reduce the occurence of perioperative hyperglycemia, glycemic variability and insulin requirements in patients undergoing cardiac surgery.


Criteria:

Inclusion Criteria: - Open cardiac surgery through sternotomy approach (coronary artery bypass, valve surgery, and any other open heart surgeries) - Surgery with use of cardiopulmonary bypass - Patients over 18 years of age - Both female and male genders - All races Exclusion Criteria: - Minimally invasive heart surgery through thoracotomy approach - Patients receiving regional analgesia such as intrathecal morphine - Patients undergoing procedures under deep hypothermic circulatory arrest - Patients with active infections such as acute infective endocarditis - Emergency surgery - Patients undergoing transplantations and ventricular assist device insertion - Patients on any mechanical circulatory support preoperatively - Patient's refusal - Allergy to remifentanil - Positive pregnancy test - Morbid obesity - End stage liver and kidney disease


NCT ID:

NCT02349152


Primary Contact:

Principal Investigator
Kathrivel Subramaniam, MD
University of Pittsburgh


Backup Contact:

N/A


Location Contact:

Pittsburg, Pennsylvania 15213
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: November 19, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.